Ser18
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser18  -  MST2 (human)

Site Information
LKkLsEDsLTkQPEE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 20831306

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 2 ) , mass spectrometry ( 1 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 2 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 2 ) , breast ( 1 )

Upstream Regulation
Putative in vivo kinases:
PLK1 (human) ( 2 )
Kinases, in vitro:
PLK1 (human) ( 2 )

Downstream Regulation
Effects of modification on MST2:
molecular association, regulation ( 2 )
Effects of modification on biological processes:
cell cycle regulation ( 2 )
Inhibit interaction with:
NEK2 (human) ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mardin BR, Agircan FG, Lange C, Schiebel E (2011) Plk1 controls the Nek2A-PP1γ antagonism in centrosome disjunction. Curr Biol 21, 1145-51
21723128   Curated Info